Cool lion concept, real photo
Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Liontown (ASX:LTR) has confirmed its first spodumene concentrate shipment will leave Kathleen Valley later this month within the same window the company has hit a production milestone of 10,000tn.

The question now remains what price can the company snag for it, and, will it be enough to keep Liontown going through a lithium downturn.

The company’s processing plant continues to be the subject of upgrades, now supporting a stockpile build where the average concentrate grade is 5.2% lithium oxide. This lines up with LTR’s expectations, it reported.

A storage facility, road transport logistics and a port shed are now all in play for Liontown in advance of its first shipment before the start of October.

Of course, the fact is that lithium prices are unlikely to hit their 2022 highs again any time soon. Shareholders in Liontown might not get the same uplift that Pilbara Minerals’ saw when it began to export spodumene in its hotly anticipated BWX auctions not that long ago.

All in all, the lithium price boom in the early 2020’s was never really about EV demand – it was largely just another COVID-borne supply chain shortage story. A tough reality, but a sound one.

“The successful mobilisation of our logistics chain and the operational readiness of our site facilities underscores our strong commitment to delivering on our commitments,” LTR CEO Tony Ottaviano said.

“As we eagerly anticipate our first shipment, scheduled for September, this progress positions us on the cusp of revenue generation, reinforcing our dedication to enhancing shareholder value.”

Liontown’s resilience through the last two years could be the bigger story.

LTR last traded at 65cps.

ltr by the numbers
More From The Market Online
The Market Online Video

Market Close: ASX 200 rallies as risk appetite returns, but business confidence weakens

The Australian sharemarket finished firmly higher today with the S&P/ASX 200 adding 106.50 points, or 1.18%, to close at 9,136.20.

EVE Health Group signs Australian compounding agreement for rapidly rising Men’s Health issue

EVE Health Group has signed an agreement with Optimal Pharmacy Plus Stafford aimed at the Australian…

Nanoveu’s EMASS signs DigiKey as Global Distributor for ECS-DoT-22

Nanoveu's wholly-owned subsidiary EMASS has signed DigiKey as its global distributor for ECS-DoT-22 system.
The Market Online Video

Wealth Within: Wall Street Tech Sinks While ASX Tech Soars

Wall Street’s technology stocks have been hammered, with the Nasdaq plunging 5.5 per cent in a single session and Nvidia falling more tha…